NERV Minerva: רווח למניה לשנה מתגלגלת

The annual percentage change in earnings per share (ttm) for Minerva Neurosciences (NERV) reflects pressure stemming from FDA restrictions on roluperidone and capital outflows. The current level is -1305.30. Minerva Neurosciences (NERV) is automating drug formula discovery via bioinformatics to reduce routine labor. Additionally, Minerva Neurosciences (NERV) is innovating therapies for sleep disorders and schizophrenia, developing molecules aimed at the social rehabilitation of patients.

This indicator measures the rolling dynamics of earnings per share (EPS) over a twelve-month period, neutralizing short-term quarterly fluctuations and identifying sustainable profitability trends. Analyzing the EPS YoY TTM shift allows for an assessment of how effectively Minerva Neurosciences (NERV) capitalizes on its innovative neurobiology developments and their subsequent impact on the company's financial results.